The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons.

The chemotherapeutic oxaliplatin causes a sensory-motor neuropathy with predominantly hyperpathic symptoms. The mechanism underlying this hyperexcitability was investigated using rat sensory nerve preparations, dorsal root ganglia and hippocampal neurons. Oxaliplatin resulted in an increase of the amplitude and duration of compound action potentials. It lengthened the refractory period of peripheral nerves suggesting an interaction with voltage-gated Na(+) channels. Application of oxaliplatin to dorsal root ganglion neurons resulted in an increase of the Na(+) current, a block of the maximal amplitude and a shift of the voltage-response relationship towards more negative membrane potentials. The effect was detectable on 13 of 18 tested cells. This observation, together with the absence of any effect on Na(+) currents of hippocampal neurons, suggests that the interaction of oxaliplatin is restricted to one or more channel subtypes. The effect of oxaliplatin could be antagonised by the Na(+) channel blocker carbamazepine which could be used to reduce side effects of oxaliplatin therapy in patients.

[1]  S. Dib-Hajj,et al.  NaN, a novel voltage-gated Na channel, is expressed preferentially in peripheral sensory neurons and down-regulated after axotomy. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[2]  P. Grafe,et al.  Function and distribution of three types of rectifying channel in rat spinal root myelinated axons. , 1987, The Journal of physiology.

[3]  E. Raymond,et al.  Oxaliplatin: mechanism of action and antineoplastic activity. , 1998, Seminars in oncology.

[4]  T A Sears,et al.  The effects of 4‐aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. , 1981, The Journal of physiology.

[5]  D. A. Brown,et al.  The mechanism of action of capsaicin on sensory C-type neurons and their axons in vitro , 1987, Neuroscience.

[6]  S. Dib-Hajj,et al.  Sodium channel α-subunit mRNAs I, II, III, NaG, Na6 and hNE (PN1): Different expression patterns in developing rat nervous system , 1997 .

[7]  P. Rougier,et al.  Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. , 1998, Seminars in oncology.

[8]  A. Leo,et al.  Oxaliplatin combined to 5‐fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer , 1998, Anti-cancer drugs.

[9]  W. Catterall,et al.  Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. , 1984, Molecular pharmacology.

[10]  P. Grafe,et al.  The effects of hyperglycaemic hypoxia on rectification in rat dorsal root axons. , 1994, The Journal of physiology.

[11]  R. Kikkawa,et al.  Tetrodotoxin-resistant sodium channels of dorsal root ganglion neurons are readily activated in diabetic rats , 1999, Neuroscience.

[12]  S. Moss,et al.  cAMP‐dependent phosphorylation of the tetrodotoxin‐resistant voltage‐dependent sodium channel SNS , 1999, The Journal of physiology.

[13]  S. Waxman,et al.  Downregulation of Tetrodotoxin-Resistant Sodium Currents and Upregulation of a Rapidly Repriming Tetrodotoxin-Sensitive Sodium Current in Small Spinal Sensory Neurons after Nerve Injury , 1997, The Journal of Neuroscience.

[14]  S. Iacobelli,et al.  Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. , 1993, European journal of cancer.

[15]  S. Waxman,et al.  Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. , 1994, Journal of neurophysiology.

[16]  S. Dib-Hajj,et al.  Spinal sensory neurons express multiple sodium channel α-subunit mRNAs , 1996 .

[17]  M. Marty,et al.  Pharmacokinetics and safety profile of oxaliplatin. , 1998, Seminars in oncology.

[18]  M. Rizzo.  Successful treatment of painful traumatic mononeuropathy with carbamazepine: insights into a possible molecular pain mechanism , 1997, Journal of the Neurological Sciences.